2-[(4-fluorobenzoyl)amino]-4-(pyridin-2-yl)thiazole | 476317-31-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[(4-fluorobenzoyl)amino]-4-(pyridin-2-yl)thiazole
• 英文别名: 4-fluoro-N-[4-(2-pyridinyl)-2-thiazolyl]-benzamide；4-fluoro-N-[4-(2-pyridyl)thiazol-2-yl]benzamide；4-fluoro-N-(4-pyridin-2-yl-1,3-thiazol-2-yl)benzamide
• CAS: 476317-31-4
• 化学式: C₁₅H₁₀FN₃OS
• 分子量: 299.328
• InChiKey: SSUOKTCXFYPRMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-碘代丙烷 、 2-[(4-fluorobenzoyl)amino]-4-(pyridin-2-yl)thiazole 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以5%的产率得到4-fluoro-N-isopropyl-N-(4-(pyridin-2-yl)thiazol-2-yl)benzamide
  参考文献：
  名称：

  Discovery and in vitro and in vivo profiles of 4-fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide as novel class of an orally active metabotropic glutamate receptor 1 (mGluR1) antagonist

  摘要：

  We identified 4-fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide 27 as a potent mGluR1 antagonist. The compound possessed excellent subtype selectivity and good PK profile in rats. It also demonstrated relatively potent antipsychotic-like effects in several animal models. Suitable for development as a PET tracer, compound 27 would have great potential for elucidation of mGluR1 functions in human. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.097
• 作为产物：
  描述：

  2-溴-1-(2-吡啶基)-1-乙酮氢溴酸 在 水 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 N,N'-羰基二咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 2-[(4-fluorobenzoyl)amino]-4-(pyridin-2-yl)thiazole
  参考文献：
  名称：

  Structure–activity relationships of 2-aminothiazoles effective against Mycobacterium tuberculosis

  摘要：

  A series of 2-aminothiazoles was synthesized based on a HTS scaffold from a whole-cell screen against Mycobacterium tuberculosis (Mtb). The SAR shows the central thiazole moiety and the 2-pyridyl moiety at C-4 of the thiazole are intolerant to modification. However, the N-2 position of the aminothiazole exhibits high flexibility and we successfully improved the antitubercular activity of the initial hit by more than 128-fold through introduction of substituted benzoyl groups at this position. N-(3-Chlorobenzoyl)-4-(2-pyridinyl)-1,3-thiazol-2-amine (55) emerged as one of the most promising analogues with a MIC of 0.024 mu M or 0.008 mu g/mL in 7H9 media and therapeutic index of nearly similar to 300. However, 55 is rapidly metabolized by human liver microsomes (t(1/2) = 28 min) with metabolism occurring at the invariant aminothiazole moiety and Mtb develops spontaneous low-level resistance with a frequency of similar to 10 (5). (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.08.048

文献信息

• COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE
  申请人：SHY Therapeutics LLC

  公开号：US20170174699A1

  公开（公告）日：2017-06-22

  Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.

  本文提供了抑制MAPK磷酸化的化合物，因此可用于治疗癌症和炎症性疾病的组合物和方法。
• Synthesis, cytotoxicity and anti-metastatic properties of new pyridyl-thiazole arene ruthenium(II) complexes
  作者：Li Wang、Yihui He、Guangya Xiang、Xianmei Shang

  DOI：10.1002/aoc.4311

  日期：2018.5

  A series of novel ruthenium(II)–cymene complexes (1–8) containing substituted pyridyl–thiazole ligands, [Ru(η6‐p‐cymene)(L)Cl]Cl (L = N,N‐chelating derivatives), have been synthesized and characterized using elemental analysis, infrared, 1H NMR and 13C NMR spectroscopies and mass spectrometry. All these complexes not only display marked cytotoxicity in vitro against three different human cancer cell

  一系列新颖的钌（II）配合物-cymene（1 - 8）含有取代的吡啶基噻唑配体，的[Ru（η 6 - p -cymene）（L）CL] CL（L = N，N-螯合衍生物），已经使用元素分析，红外，1 H NMR和13 C NMR光谱法和质谱法对这些化合物进行了合成和表征。所有这些复合物不仅在体外显示出明显的细胞毒性对三种不同的人类癌细胞系（HeLa，A549和MDA-MB-231）具有抗性，但在亚细胞毒性浓度下也显示出有希望的抗转移活性。细胞周期分析表明，钌（II）复合物诱导的生长抑制主要是由S期细胞周期停滞引起的。进一步的蛋白质水平分析表明，化合物5可能通过p53独立机制发挥抗肿瘤活性。
• Compounds for the treatment of cancer and inflammatory disease
  申请人：SHY Therapeutics LLC

  公开号：US10221191B2

  公开（公告）日：2019-03-05

  Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.

  本文提供的化合物可抑制 MAPK 磷酸化，因此可用于治疗癌症和炎症性疾病的组合物和方法中。
• Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
  申请人：SHY Therapeutics LLC

  公开号：US10588894B2

  公开（公告）日：2020-03-17

  Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.

  本文提供了通过化合物与 Ras 超家族蛋白（在某些情况下包括 K-Ras 及其突变体）的 GTP 结合结构域结合，治疗涉及 Ras 超家族信号异常的癌症、炎症性疾病、rasopathies 和纤维化疾病的方法和组合物，以及检测此类组合物的新方法。
• Synthesis and biological evaluation of 2-aminothiazole derivatives as antimycobacterial and antiplasmodial agents
  作者：Faith Mjambili、Mathew Njoroge、Krupa Naran、Carmen De Kock、Peter J. Smith、Valerie Mizrahi、Digby Warner、Kelly Chibale

  DOI：10.1016/j.bmcl.2013.12.022

  日期：2014.1

  A series of compounds derived from the 2-amino-4-(2-pyridyl) thiazole scaffold was synthesized and tested for in vitro antimycobacterial activity against the Mycobacterium tuberculosis H37Rv strain, antiplasmodial activity against the chloroquine sensitive NF54 Plasmodium falciparum strain and cytotoxicity on a mammalian cell line. Optimal antimycobacterial activity was found with compounds with a 2-pyridyl ring at position 4 of the thiazole scaffold, a substituted phenyl ring at the 2-amino position, and an amide linker between the scaffold and the substituted phenyl. The antiplasmodial activity was best with compounds that had the phenyl ring substituted with hydrophobic electron withdrawing groups. (C) 2013 Elsevier Ltd. All rights reserved.